Limited Coverage Drugs - Adalimumab for the treatment of Psoriatic Arthritis

Generic Name

adalimumab

Strength

40 mg / 0.8 ml
Form subcutaneous injection solution

Special Authority Criteria

Approval Period

For the treatment of Psoriatic Arthritis according to established criteria described in Special Authority Request forms 5360 (Initial/Switch) and 5361 (Renewal), below.

Coverage of adalimumab for the treatment of Psoriatic Arthritis is only available when adalimumab is prescribed by a rheumatologist.

First approval: 1 year
Renewal: 1 year to indefinite

Practitioner Exemptions

  • None

Special Notes

The maximum covered allowable supply of adalimumab is 28 days per fill.

Special Authority Request Form(s)